# Replimune Group, Inc.: financial statements, quarterly

REPL · Nasdaq · CIK 1737953 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Mar 31

Pages: [Overview](/companies/repl.md) · [Financials](/companies/repl/financials.md) · [Filings](/companies/repl/filings.md) · [Insiders](/companies/repl/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/repl/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q4 FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [49.1](/filings/0001737953-24-000015.md) | [42.8](/filings/0001737953-25-000004.md) | [42.6 d](/filings/0001737953-25-000009.md) | [43.0](/filings/0001737953-25-000013.md) | [43.4](/filings/0001628280-25-049884.md) | [48.0](/filings/0001628280-26-004805.md) | [54.0 d](/filings/0001628280-26-045886.md) | [57.8](/filings/0001628280-26-057099.md) | [57.9](/filings/0001628280-25-049884.md) | [53.1](/filings/0001628280-26-004805.md) | [52.3 d](/filings/0001628280-26-045886.md) | [49.3](/filings/0001628280-26-057099.md) |
| Selling, general and administrative | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [32.6](/filings/0001628280-26-057099.md) | not reported | not reported | not reported | [19.0](/filings/0001628280-26-057099.md) |
| Operating income | $m | [(63.8)](/filings/0001737953-24-000015.md) | [(56.5)](/filings/0001737953-25-000004.md) | [(58.8) d](/filings/0001737953-25-000009.md) | [(57.4)](/filings/0001737953-25-000013.md) | [(58.9)](/filings/0001628280-25-049884.md) | [(66.0)](/filings/0001628280-26-004805.md) | [(79.3) d](/filings/0001628280-26-045886.md) | [(90.4)](/filings/0001628280-26-057099.md) | [(84.3)](/filings/0001628280-25-049884.md) | [(71.9)](/filings/0001628280-26-004805.md) | [(73.3) d](/filings/0001628280-26-045886.md) | [(68.2)](/filings/0001628280-26-057099.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [(0.2)](/filings/0001737953-24-000015.md) | [0.5](/filings/0001737953-25-000004.md) | [(0.1) d](/filings/0001737953-25-000009.md) | [0.0](/filings/0001737953-25-000013.md) | [0.0](/filings/0001628280-25-049884.md) | [0.6](/filings/0001628280-26-004805.md) | [(0.1) d](/filings/0001628280-26-045886.md) | [0.0](/filings/0001737953-25-000013.md) | [0.0](/filings/0001628280-25-049884.md) | [(0.3)](/filings/0001628280-26-004805.md) | [(0.2) d](/filings/0001628280-26-045886.md) | not reported |
| Net income | $m | [(60.0)](/filings/0001737953-25-000004.md) | [(51.1)](/filings/0001737953-25-000004.md) | [(55.1) d](/filings/0001737953-25-000009.md) | [(53.8)](/filings/0001628280-26-004805.md) | [(53.1)](/filings/0001628280-26-004805.md) | [(66.3)](/filings/0001628280-26-004805.md) | [(74.1) d](/filings/0001628280-26-045886.md) | [(86.7)](/filings/0001628280-26-057099.md) | [(83.1)](/filings/0001628280-26-004805.md) | [(70.9)](/filings/0001628280-26-004805.md) | [(73.2) d](/filings/0001628280-26-045886.md) | [(69.8)](/filings/0001628280-26-057099.md) |
| Diluted EPS | $ per share | [(0.90)](/filings/0001737953-24-000015.md) | [(0.77)](/filings/0001737953-25-000004.md) | not reported | [(0.78)](/filings/0001737953-25-000013.md) | [(0.68)](/filings/0001628280-25-049884.md) | [(0.79)](/filings/0001628280-26-004805.md) | not reported | [(0.95)](/filings/0001628280-26-057099.md) | [(0.90)](/filings/0001628280-25-049884.md) | [(0.77)](/filings/0001628280-26-004805.md) | not reported | [(0.72)](/filings/0001628280-26-057099.md) |
| Basic EPS | $ per share | [(0.90)](/filings/0001737953-24-000015.md) | [(0.77)](/filings/0001737953-25-000004.md) | not reported | [(0.78)](/filings/0001737953-25-000013.md) | [(0.68)](/filings/0001628280-25-049884.md) | [(0.79)](/filings/0001628280-26-004805.md) | not reported | [(0.95)](/filings/0001628280-26-057099.md) | [(0.90)](/filings/0001628280-25-049884.md) | [(0.77)](/filings/0001628280-26-004805.md) | not reported | [(0.72)](/filings/0001628280-26-057099.md) |

- Revenue: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [76.0](/filings/0001737953-23-000017.md) | [97.7](/filings/0001737953-24-000004.md) | [74.5](/filings/0001737953-25-000009.md) | [152](/filings/0001737953-24-000013.md) | [113](/filings/0001737953-24-000015.md) | [172](/filings/0001737953-25-000004.md) | [111](/filings/0001628280-26-045886.md) | [97.4](/filings/0001737953-25-000013.md) | [102](/filings/0001628280-25-049884.md) | [123](/filings/0001628280-26-004805.md) | [209](/filings/0001628280-26-057099.md) | [185](/filings/0001628280-26-057099.md) |
| Current assets | $m | [508](/filings/0001737953-23-000017.md) | [479](/filings/0001737953-24-000004.md) | [434](/filings/0001737953-25-000009.md) | [480](/filings/0001737953-24-000013.md) | [443](/filings/0001737953-24-000015.md) | [548](/filings/0001737953-25-000004.md) | [496](/filings/0001628280-26-045886.md) | [413](/filings/0001737953-25-000013.md) | [334](/filings/0001628280-25-049884.md) | [280](/filings/0001628280-26-004805.md) | [279](/filings/0001628280-26-057099.md) | [201](/filings/0001628280-26-057099.md) |
| Total assets | $m | [562](/filings/0001737953-23-000017.md) | [533](/filings/0001737953-24-000004.md) | [488](/filings/0001737953-25-000009.md) | [535](/filings/0001737953-24-000013.md) | [498](/filings/0001737953-24-000015.md) | [604](/filings/0001737953-25-000004.md) | [551](/filings/0001628280-26-045886.md) | [470](/filings/0001737953-25-000013.md) | [389](/filings/0001628280-25-049884.md) | [334](/filings/0001628280-26-004805.md) | [332](/filings/0001628280-26-057099.md) | [252](/filings/0001628280-26-057099.md) |
| Current liabilities | $m | [39.8](/filings/0001737953-23-000017.md) | [38.7](/filings/0001737953-24-000004.md) | [40.4](/filings/0001737953-25-000009.md) | [35.7](/filings/0001737953-24-000013.md) | [43.8](/filings/0001737953-24-000015.md) | [47.9](/filings/0001737953-25-000004.md) | [62.4](/filings/0001628280-26-045886.md) | [59.6](/filings/0001737953-25-000013.md) | [52.9](/filings/0001628280-25-049884.md) | [50.1](/filings/0001628280-26-004805.md) | [58.2](/filings/0001628280-26-057099.md) | [38.4](/filings/0001628280-26-057099.md) |
| Total liabilities | $m | [97.2](/filings/0001737953-23-000017.md) | [111](/filings/0001737953-24-000004.md) | [113](/filings/0001737953-25-000009.md) | [109](/filings/0001737953-24-000013.md) | [117](/filings/0001737953-24-000015.md) | [121](/filings/0001737953-25-000004.md) | [135](/filings/0001628280-26-045886.md) | [133](/filings/0001737953-25-000013.md) | [126](/filings/0001628280-25-049884.md) | [123](/filings/0001628280-26-004805.md) | [166](/filings/0001628280-26-057099.md) | [147](/filings/0001628280-26-057099.md) |
| Long-term debt | $m | [29.2](/filings/0001737953-23-000017.md) | [44.4](/filings/0001737953-24-000004.md) | [44.8](/filings/0001737953-25-000009.md) | [45.2](/filings/0001737953-24-000013.md) | [45.6](/filings/0001737953-24-000015.md) | [46.0](/filings/0001737953-25-000004.md) | [46.4](/filings/0001628280-26-045886.md) | [46.8](/filings/0001737953-25-000013.md) | [47.2](/filings/0001628280-25-049884.md) | [47.6](/filings/0001628280-26-004805.md) | [83.3](/filings/0001628280-26-057099.md) | [84.1](/filings/0001628280-26-057099.md) |
| Shareholders' equity | $m | [465](/filings/0001737953-25-000004.md) | [422](/filings/0001737953-25-000004.md) | [375](/filings/0001628280-26-045886.md) | [426](/filings/0001628280-26-004805.md) | [381](/filings/0001628280-26-004805.md) | [482](/filings/0001628280-26-004805.md) | [416](/filings/0001628280-26-057099.md) | [337](/filings/0001628280-26-057099.md) | [263](/filings/0001628280-26-004805.md) | [211](/filings/0001628280-26-004805.md) | [166](/filings/0001628280-26-057099.md) | [106](/filings/0001628280-26-057099.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt, us-gaap:LongTermDebtNoncurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q4 FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(43.6) d](/filings/0001737953-24-000015.md) | [(47.1) d](/filings/0001737953-25-000004.md) | [(46.2) d](/filings/0001737953-25-000009.md) | [(49.2)](/filings/0001737953-25-000013.md) | [(38.6) d](/filings/0001628280-25-049884.md) | [(50.7) d](/filings/0001628280-26-004805.md) | [(53.7) d](/filings/0001628280-26-045886.md) | [(77.0)](/filings/0001628280-26-057099.md) | [(81.2) d](/filings/0001628280-25-049884.md) | [(66.0) d](/filings/0001628280-26-004805.md) | [(56.2) d](/filings/0001628280-26-045886.md) | [(75.7)](/filings/0001628280-26-057099.md) |
| Capital expenditure | $m | [1.8 d](/filings/0001737953-24-000015.md) | [1.7 d](/filings/0001737953-25-000004.md) | [1.7 d](/filings/0001737953-25-000009.md) | [1.7](/filings/0001737953-25-000013.md) | [2.1 d](/filings/0001628280-25-049884.md) | [1.8 d](/filings/0001628280-26-004805.md) | [1.1 d](/filings/0001628280-26-045886.md) | [2.7](/filings/0001628280-26-057099.md) | [1.3 d](/filings/0001628280-25-049884.md) | [0.1 d](/filings/0001628280-26-004805.md) | [0.0 d](/filings/0001628280-26-045886.md) | [0.0](/filings/0001628280-26-057099.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets

## Shares

| Line item | Unit | Q2 FY2023 (2022-09-30) | Q3 FY2023 (2022-12-31) | Q1 FY2024 (2023-06-30) | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [54.8](/filings/0001737953-23-000017.md) | [57.9](/filings/0001737953-24-000004.md) | [66.4](/filings/0001737953-24-000013.md) | [66.6](/filings/0001737953-24-000015.md) | [66.6](/filings/0001737953-25-000004.md) | [69.2](/filings/0001737953-25-000013.md) | [78.6](/filings/0001628280-25-049884.md) | [83.5](/filings/0001628280-26-004805.md) | [91.5](/filings/0001628280-26-057099.md) | [91.9](/filings/0001628280-25-049884.md) | [92.2](/filings/0001628280-26-004805.md) | [96.9](/filings/0001628280-26-057099.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 94,219,634 at 2026-08-11, from the cover of the [10-Q filed 2026-08-14](/filings/0001628280-26-057099.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.